AU1753892A - Mammalian gap-43 compositions and methods of use - Google Patents

Mammalian gap-43 compositions and methods of use

Info

Publication number
AU1753892A
AU1753892A AU17538/92A AU1753892A AU1753892A AU 1753892 A AU1753892 A AU 1753892A AU 17538/92 A AU17538/92 A AU 17538/92A AU 1753892 A AU1753892 A AU 1753892A AU 1753892 A AU1753892 A AU 1753892A
Authority
AU
Australia
Prior art keywords
compositions
methods
mammalian gap
mammalian
gap
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU17538/92A
Inventor
Howard J. Federoff
Mark C. Fishman
Stephen M Strittmatter
Dario Valenzuela
Mauricio X. Zuber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Publication of AU1753892A publication Critical patent/AU1753892A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/38—Vector systems having a special element relevant for transcription being a stuffer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AU17538/92A 1991-04-10 1992-04-10 Mammalian gap-43 compositions and methods of use Abandoned AU1753892A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68345591A 1991-04-10 1991-04-10
US683455 1991-04-10

Publications (1)

Publication Number Publication Date
AU1753892A true AU1753892A (en) 1992-11-17

Family

ID=24744128

Family Applications (1)

Application Number Title Priority Date Filing Date
AU17538/92A Abandoned AU1753892A (en) 1991-04-10 1992-04-10 Mammalian gap-43 compositions and methods of use

Country Status (2)

Country Link
AU (1) AU1753892A (en)
WO (1) WO1992018138A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994004562A1 (en) * 1992-08-13 1994-03-03 The General Hospital Corporation Mammalian gap-43 compositions and methods of use
AU1304895A (en) * 1993-12-07 1995-06-27 General Hospital Corporation, The Peptides to overcome inhibition of nerve growth
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
WO2009143865A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2009143864A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
CA2807036C (en) 2010-10-14 2018-01-16 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
PL3013353T3 (en) 2013-06-26 2021-09-20 Xigen Inflammation Ltd. Cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of cystitis
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases

Also Published As

Publication number Publication date
WO1992018138A1 (en) 1992-10-29

Similar Documents

Publication Publication Date Title
AU3076189A (en) Novel compositions and methods of use thereof
AU1913792A (en) Novel derivatives of thiopyranopyrrole and preparation thereof
AU626396B2 (en) Composition and use
ZA949668B (en) Optionally crosslinkable coatings compositions and methods of use
AU7294194A (en) Substituted heterocyclylisoquinolinium salts and compositions and method of use thereof
AU8154294A (en) Methods of inhibiting atrophy of the skin and vagina
AU6959694A (en) Antineoplastic compositions and methods of use
AU2065992A (en) Herbicidal compositions and methods of preparing and using the same
AU2114792A (en) Win 49596-finasteride method of use and compositions
AU1753892A (en) Mammalian gap-43 compositions and methods of use
AU8653091A (en) Crystallizing enamel composition and method of using the same
AU7400091A (en) Inhibitors of the advanced glycosylation of proteins and methods of use therefor
HU9600241D0 (en) Mutable composition and methods of use thereof
EP0673385A4 (en) Mammalian gap-43 compositions and methods of use.
AU3220993A (en) Crystallizing enamel composition and method of making and using the same
AU2490492A (en) Process for the preparation of beta-phenylisoserine derivatives and use thereof
AU651992B2 (en) Polyethylene terephthalate compositions and methods of using thereof
AU8427091A (en) Gamma-carboxylase and methods of use
AU8192691A (en) Method of treatment and compositions therefore
AU1714792A (en) Glass composition and use
AU4468093A (en) Composition and methods for the generation of bone
AU4243389A (en) Antimicrobial composition and method of use
AU6723294A (en) Use of simmondsine
GB9525254D0 (en) Therapeutic compositions and methods of use
AU6651794A (en) Automatisation of electro-oculographic examination